These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 21690572

  • 1. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC, Santoni-Rugiu E, Sørensen JB.
    Clin Cancer Res; 2011 Aug 01; 17(15):5205-14. PubMed ID: 21690572
    [Abstract] [Full Text] [Related]

  • 2. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 01; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.
    Cancer Chemother Pharmacol; 2014 Oct 01; 74(4):777-86. PubMed ID: 25107571
    [Abstract] [Full Text] [Related]

  • 4. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M, Lafanéchère L, Penet A, Peiller EL, Dumontet C.
    Clin Cancer Res; 2005 Aug 01; 11(15):5481-6. PubMed ID: 16061864
    [Abstract] [Full Text] [Related]

  • 5. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
    Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW.
    Lung Cancer; 2012 Jul 01; 77(1):9-15. PubMed ID: 22306125
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC, Timsit JF, Couraud S, Merle P, Moro-Sibilot D, Perol M, Mastroianni B, Souquet PJ, Girard N, Jeannin G, Romand P, Chatellain P, Vesin A, Brambilla C, Brambilla E.
    Lung Cancer; 2014 Feb 01; 83(2):182-8. PubMed ID: 24388706
    [Abstract] [Full Text] [Related]

  • 7. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
    Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E.
    Cancer Chemother Pharmacol; 2012 Nov 01; 70(5):743-54. PubMed ID: 22960937
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE.
    J Clin Oncol; 2008 Apr 10; 26(11):1886-92. PubMed ID: 18398154
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Burris HA, Morrissey LH, Thomas M, Erland JB, Butts JA, Joseph G, Kalman L, Greco FA.
    Cancer J; 2000 Apr 10; 6(3):151-6. PubMed ID: 10882330
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.
    J Clin Oncol; 2009 Apr 20; 27(12):2038-45. PubMed ID: 19307503
    [Abstract] [Full Text] [Related]

  • 11. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
    Sève P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T.
    Clin Cancer Res; 2007 Feb 01; 13(3):994-9. PubMed ID: 17289895
    [Abstract] [Full Text] [Related]

  • 12. Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.
    Jahnke K, Keilholz U, Lüftner D, Thiel E, Schmittel A.
    Anticancer Res; 2011 Jan 01; 31(1):317-23. PubMed ID: 21273617
    [Abstract] [Full Text] [Related]

  • 13. [Class III beta tubulin expression in nonsmall cell lung cancer].
    Sève P, Dumontet C.
    Rev Mal Respir; 2010 Apr 01; 27(4):383-6. PubMed ID: 20403547
    [Abstract] [Full Text] [Related]

  • 14. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
    Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C.
    Lung Cancer; 2012 Jul 01; 77(1):116-20. PubMed ID: 22361218
    [Abstract] [Full Text] [Related]

  • 15. Is class III beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence.
    Hirai Y, Yoshimasu T, Oura S, Ota F, Naito K, Nishiguchi H, Hashimoto S, Okamura Y.
    Anticancer Res; 2011 Mar 01; 31(3):999-1005. PubMed ID: 21498728
    [Abstract] [Full Text] [Related]

  • 16. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, Kang CH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Kim YW, Kim JH, Heo DS, Bang YJ.
    J Thorac Oncol; 2010 Mar 01; 5(3):320-5. PubMed ID: 20087230
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
    Chen P, Li J, Ge LP, Dai CH, Li XQ.
    Respirology; 2010 Apr 01; 15(3):501-9. PubMed ID: 20210890
    [Abstract] [Full Text] [Related]

  • 18. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2008 Sep 01; 61(3):369-77. PubMed ID: 18308419
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
    Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E, Villanueva-Rodríguez G, Cerón-Lizárraga TL, Martínez-Barrera L, Vázquez-Manríquez ME, Ríos-Trejo MA, Alvarez-Avitia MA, Hernández-Pedro N, Rojas-Marín C, De la Garza J.
    J Clin Oncol; 2010 Jul 20; 28(21):3463-71. PubMed ID: 20547984
    [Abstract] [Full Text] [Related]

  • 20. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G.
    Clin Lung Cancer; 2008 Sep 20; 9(5):280-4. PubMed ID: 18824450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.